Trial Profile
Phase 2 study of RK-023 patients with androgenetic alopecia (male pattern baldness) -A study for safety and preliminary estimation of hair re-growth in male subjects with androgenetic alopecia treated for 13 weeks with RK-023-
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jun 2018
Price :
$35
*
At a glance
- Drugs RK 023 (Primary)
- Indications Alopecia
- Focus Adverse reactions; Therapeutic Use
- Sponsors R-Tech Ueno
- 24 Jan 2011 Results were reported in a R-Tech Ueno media release.